A comparison of the efficacy and safety of quinapril with that of enalapril in the treatment of mild to moderate essential hypertension.
This twenty-eight-week double-blind study in patients with mild to moderate essential hypertension showed quinapril (10, 20, and 40 mg/day) to be similarly effective to enalapril at the same doses in producing clinically significant reductions in sitting DBP. Hydrochlorothiazide could be safely added to quinapril therapy in nonresponders. Quinapril and enalapril were well tolerated. Both agents can safely be administered as first-line therapy.
Taylor
S H
SH
University Department of Cardiovascular Studies, General Infirmary, Leeds, England.
D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004656:Enalapril / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007546:Isoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D000077583:Quinapril; D011897:Random Allocation; D044005:Tetrahydroisoquinolines
D000806:Angiotensin-Converting Enzyme Inhibitors; D007546:Isoquinolines; D044005:Tetrahydroisoquinolines; D004656:Enalapril; D000077583:Quinapril